RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hemagen Diagnostics Stock

Hemagen Diagnostics Revenue 2024

Hemagen Diagnostics Revenue

4.04 M USD

Ticker

HMGN

ISIN

US4235011057

WKN

885724

In 2024, Hemagen Diagnostics's sales reached 4.04 M USD, a -21.38% difference from the 5.14 M USD sales recorded in the previous year.

The Hemagen Diagnostics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
20124.0439,92
20115.1438,14
20105.2245,14
20095.4238,25
20086.3843,48
20074.4941,92
20064.7839,75
20057.5925,16
20047.4728,78
20038.4735,30
20029.530,95
200110.9731,08
20001112,55
199914.5921,80
199812.3340,79
199712.9941,49
199610.2238,85
19953.9644,70
19942.3650,00
19931.8158,56

Hemagen Diagnostics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hemagen Diagnostics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hemagen Diagnostics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hemagen Diagnostics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hemagen Diagnostics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hemagen Diagnostics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hemagen Diagnostics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hemagen Diagnostics’s growth potential.

Hemagen Diagnostics Revenue, EBIT and net profit per share

DateHemagen Diagnostics RevenueHemagen Diagnostics EBITHemagen Diagnostics Net Income
20124.04 M undefined-437,920 undefined-907,320 undefined
20115.14 M undefined-472,710 undefined-880,480 undefined
20105.22 M undefined235,950 undefined-156,310 undefined
20095.42 M undefined-348,000 undefined-807,000 undefined
20086.38 M undefined118,000 undefined428,000 undefined
20074.49 M undefined-159,000 undefined-850,000 undefined
20064.78 M undefined-170,000 undefined310,000 undefined
20057.59 M undefined-730,000 undefined-1.34 M undefined
20047.47 M undefined-510,000 undefined-3.6 M undefined
20038.47 M undefined250,000 undefined-1.27 M undefined
20029.5 M undefined-670,000 undefined-1.76 M undefined
200110.97 M undefined-260,000 undefined-2.2 M undefined
200011 M undefined-3.37 M undefined-5.13 M undefined
199914.59 M undefined-2.73 M undefined-5.16 M undefined
199812.33 M undefined100,000 undefined10,000 undefined
199712.99 M undefined510,000 undefined410,000 undefined
199610.22 M undefined-50,000 undefined-460,000 undefined
19953.96 M undefined-850,000 undefined-990,000 undefined
19942.36 M undefined-1.13 M undefined-1.11 M undefined
19931.81 M undefined-630,000 undefined-1.25 M undefined

Hemagen Diagnostics stock margins

The Hemagen Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hemagen Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hemagen Diagnostics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hemagen Diagnostics's sales revenue. A higher gross margin percentage indicates that the Hemagen Diagnostics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hemagen Diagnostics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hemagen Diagnostics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hemagen Diagnostics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hemagen Diagnostics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hemagen Diagnostics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hemagen Diagnostics Margin History

Hemagen Diagnostics Gross marginHemagen Diagnostics Profit marginHemagen Diagnostics EBIT marginHemagen Diagnostics Profit margin
201239.92 %-10.83 %-22.45 %
201138.14 %-9.19 %-17.13 %
201045.14 %4.52 %-2.99 %
200938.25 %-6.42 %-14.89 %
200843.48 %1.85 %6.71 %
200741.92 %-3.54 %-18.94 %
200639.75 %-3.56 %6.49 %
200525.16 %-9.62 %-17.65 %
200428.78 %-6.83 %-48.19 %
200335.3 %2.95 %-14.99 %
200230.95 %-7.05 %-18.53 %
200131.08 %-2.37 %-20.05 %
200012.55 %-30.64 %-46.64 %
199921.8 %-18.71 %-35.37 %
199840.79 %0.81 %0.08 %
199741.49 %3.93 %3.16 %
199638.85 %-0.49 %-4.5 %
199544.7 %-21.46 %-25 %
199450 %-47.88 %-47.03 %
199358.56 %-34.81 %-69.06 %

Hemagen Diagnostics Aktienanalyse

What does Hemagen Diagnostics do?

Hemagen Diagnostics Inc is a company that was founded in 1985. The company is based in Columbia, Maryland and is involved in medical diagnostics. Hemagen specializes in the development of diagnostic test kits that help doctors and laboratories identify and treat medical conditions and diseases. Hemagen Diagnostics offers a wide range of products in the field of diagnostics and medical research. Their offerings include diagnostic test kits for autoimmune diseases, infectious diseases, enzymes, proteins, and hormones. These test kits are used by medical professionals and laboratories worldwide. The business model of Hemagen Diagnostics is focused on providing its customers with the best diagnostic test kits on the market. The company has developed a wide range of products and services for a broad spectrum of medical conditions and diseases. Hemagen Diagnostics' core business is the production of test kits for laboratories and medical professionals. One of Hemagen Diagnostics' main areas of focus is disease diagnosis. The company has developed an extensive range of diagnostic test kits that facilitate the diagnosis of various diseases. This includes test kits for diseases such as HIV, hepatitis, and infectious diseases like chlamydia and gonorrhea. Hemagen also produces test kits for autoimmune diseases such as rheumatoid arthritis and lupus. Another focus of Hemagen Diagnostics is the development of test kits for medical research. The company has created a wide selection of test kits that can be used for research projects. This includes test kits for hormones, proteins, and enzymes. These test kits are suitable for a range of research applications such as biomarker identification and the study of metabolic processes. Over the years, Hemagen Diagnostics has expanded and improved its range of products and services. The company has continuously expanded and enhanced its division for the development of diagnostic test kits. It has also established a number of partnerships with other companies and institutes in the field of medical diagnostics. In conclusion, Hemagen Diagnostics Inc is a leading provider of diagnostic test kits for medical diagnostics and research. The company specializes in the development of state-of-the-art tests for disease diagnosis and the investigation of biomolecular processes. Hemagen Diagnostics has a strong reputation within the medical community and is continuously working on improving and expanding its product range. Hemagen Diagnostics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Hemagen Diagnostics's Sales Figures

The sales figures of Hemagen Diagnostics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Hemagen Diagnostics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Hemagen Diagnostics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Hemagen Diagnostics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Hemagen Diagnostics stock

How much revenue did Hemagen Diagnostics generate this year?

Hemagen Diagnostics has achieved a revenue of 4.04 M USD this year.

How much was the turnover of the company Hemagen Diagnostics compared to the previous year?

The revenue of Hemagen Diagnostics has increased by -21.38% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Hemagen Diagnostics?

The revenue of Hemagen Diagnostics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Hemagen Diagnostics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Hemagen Diagnostics so important for investors?

The revenue of Hemagen Diagnostics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Hemagen Diagnostics pay?

Over the past 12 months, Hemagen Diagnostics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hemagen Diagnostics is expected to pay a dividend of 0 USD.

What is the dividend yield of Hemagen Diagnostics?

The current dividend yield of Hemagen Diagnostics is .

When does Hemagen Diagnostics pay dividends?

Hemagen Diagnostics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hemagen Diagnostics?

Hemagen Diagnostics paid dividends every year for the past 0 years.

What is the dividend of Hemagen Diagnostics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hemagen Diagnostics located?

Hemagen Diagnostics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hemagen Diagnostics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hemagen Diagnostics from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Hemagen Diagnostics pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Hemagen Diagnostics in the year 2023?

In the year 2023, Hemagen Diagnostics distributed 0 USD as dividends.

In which currency does Hemagen Diagnostics pay out the dividend?

The dividends of Hemagen Diagnostics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hemagen Diagnostics

Our stock analysis for Hemagen Diagnostics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hemagen Diagnostics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.